At Least 13 Chinese Biopharma Companies Secured New Funding in July, Advancing Diverse Innovative Pipelines

　　【Pharmaceutical Network Industry DynamicsAccording to the review, in July (as of July 28), at least 13 companies in China's biopharmaceuticals field completed new rounds of financing. The companies involved include BAO PHARMA, Rona Therapeutics, Xiatong Bio, AusperBio, Zhiyuan Medical Technology, Pukang Bio, UniXelI BIOTECHNOLOGY, ASOcura, Guangzhou Colony Biotechnology Co., Ltd., AnBogen Therapeutics, Nanjing Sike Medicine Industry Co.,Ltd., Bivision Pharmaceuticals, and Innovmab Therapeutics.
 

As announced by LuYe Pharma, Shenzhen LuYe has received a strategic investment of up to 1.6 billion yuan from Shenzhen LuYe Private Equity Investment Fund. This 1.6-billion-yuan strategic financing will undoubtedly accelerate the rise of Shenzhen LuYe. According to the announcement, this investment will provide the group with more abundant cash flow. At the same time, it will focus on original innovation in R&D and strengthen the development of next-generation innovative anti-cancer drugs. In addition, the group will also integrate platform advantages and resources to actively achieve the transformation of new marketing models in the Greater Bay Area and even throughout China, supporting Shenzhen LuYe's business development in terms of market, medicine, access, and sales, thereby enhancing Shenzhen LuYe's competitive advantage in the market.
 

It is reported that currently, Luye Pharma focuses on the fields of oncology, central nervous system, cardiovascular, digestive and metabolic diseases. In the past month, Luye Pharma has successively obtained approval for two central nervous system drugs in China: Mebiri (Paliperidone Palmitate Injection) for the treatment of schizophrenia, and Jin Youping (Ropinirole Hydrochloride Microspheres for Injection), a long-acting microsphere formulation for the treatment of Parkinson's disease.
 

Bivision Pharmaceuticals Announces Completion of Nearly 100 Million Yuan in Series A Financing. The funds from this round will primarily be used for global Phase I/II clinical trials of JH02, IND applications and clinical development in both China and the U.S. for 68Ga-JH03/177Lu-JH04, as well as preclinical research and international cooperation for several subsequent innovative pipeline projects.
 

It is reported that, to date, Bivision Pharmaceuticals has built a proprietary technology platform for targeted radiopharmaceutical development, used for ligand screening, modulation of conjugation factors (J-Linker), and clinical translation. Through the J-Linker multifunctional conjugation platform, the exposure of drugs at disease sites can be effectively increased while reducing exposure to other organs, thereby bringing better therapeutic effects and a wider safety window to Bivision Pharmaceuticals' ongoing pipeline.
 

Innovmab Therapeutics Completes Angel+ Round Financing from Dandelion (Shenzhen) Medical Venture Capital. The funds will be used to deeply integrate the proteomics technology platform with drug development, creating multiple promising ADC pipelines.
 

It is reported that Innovmab Therapeutics currently has multiple preclinical ADC drug pipelines with innovative concepts in drug development, including unique target products based on more than 10 years of academic accumulation, which can be developed into first-in-class products, giving the company a differentiated competitive advantage.
 

In July, BAO PHARMA announced the completion of a C-round financing worth hundreds of millions of RMB. This round of financing will be used to further promote the R&D and industrialization process of BAO PHARMA's products, enhancing its market competitiveness and industry position. Relevant personnel from BAO PHARMA stated that the company uses samples from a scaled industrialization platform for clinical trials during the Phase II and III clinical stages. The purpose of this strategy is to effectively accelerate the industrial implementation of scientific and technological achievements under the existing pharmaceutical regulatory policies to meet extensive clinical needs and truly achieve the "upgrade and replacement" of biopharmaceutical products in terms of market scale.
 

Rona Therapeutics Announces Completion of $35 Million Series A+ Financing. Rona Therapeutics is committed to the research and development of nucleic acid innovative drugs for the treatment of metabolic diseases and central nervous system degenerative diseases. This round of financing will be used to advance the innovative siRNA metabolic pipeline projects into global development and expand the extracellular liver delivery platform in the central nervous system and other fields.
 

Xiatong Biotechnology Announces Investment from a Listed Company's Fund to Accelerate Investigator-Initiated Clinical Trials (IIT) and New Drug Clinical Trial Applications (IND) for Demyelinating Diseases and Other Pipelines.
 

AusperBio Announces Completion of $37 Million Series A Financing Round; Funds to Accelerate Phase II Clinical Trials of AHB-137, a Potential Cornerstone Cure for Hepatitis B, Combination Therapy Exploration, CMC Production, and Expansion of the Proprietary Med-Oligo™ Technology Platform and Pipeline.
 

Zhiyuan Medical Technology (Shanghai) Co., Ltd. announced the completion of an angel round of financing worth tens of millions of yuan. The funds raised will mainly be used for the company’s development of cell therapy products targeting lumbar disc degeneration, among other initiatives.
 

Pukang Biotechnology Announces Completion of External Financing, Introducing Yanshan Technology as a Financial Investor with RMB 100 Million in Funding. The company's main product is the freeze-dried live attenuated hepatitis A vaccine.
 

UniXelI BIOTECHNOLOGY Announces Completion of Tens of Millions in Series A+ Financing; Funds to Advance Innovative Pipeline in Stem Cell Therapy and Accelerate Clinical Translation
 

ASOcura Completes Nearly 100 Million Yuan in Series A Financing; Proceeds to Accelerate Development of Products for Duchenne Muscular Dystrophy (DMD) and Spinocerebellar Ataxia Type 3 (SCA3) Indications.
 

Guangzhou Colony Biotechnology Co., Ltd. announced the completion of a 300 million yuan C+ round of financing. The funds will mainly be used to advance the scaled production and commercialization of more bio-innovative products, as well as to expand the company's proprietary commercial microbial strain library and component library, and further improve the biomanufacturing technology platform.
 

AnBogen Therapeutics announced the successful completion of its Series A+ funding round, raising NT$220 million. The proceeds from this Series A+ round will primarily be used to support Phase 2 clinical trials for the combination therapy of ABT-301 and a PD-1 inhibitor in treating microsatellite stable (MSS) metastatic colorectal cancer.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.